Thursday, July 27, 2017


QURE uniQure N.V. gains 45% Jul 27, 2017

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company offers Glybera, a gene therapy product for the treatment of patients with lipoprotein lipase deficiency. It is also developing AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-110, a gene therapy that has been completed Phase I/II clinical trial for the treatment of sanfilippo B syndrome; AAV2/glial cell line-derived neurotrophic factor, which is in Phase I clinical trial for the treatment of parkinson's disease; S100A1, a preclinical product candidate for the treatment of congestive heart failure; AMT-130 for the treatment of huntington's disease; and AAV5 for the treatment of hemophilia A. The company has collaborations with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Treeway B.V., Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive